Kennedy-Nasser Alana A, Brenner Malcolm K
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA.
Curr Opin Hematol. 2007 Nov;14(6):616-24. doi: 10.1097/MOH.0b013e3282ef615a.
The separation of graft versus host disease from graft versus leukaemia reactivity and the reconstitution of immunity to infectious agents are the main goals of T-cell therapy after allogeneic hematopoietic stem cell transplantation. We describe how an improved understanding of T-cell mediated graft versus leukemia and of antiviral responses is providing effective approaches to T-cell immunotherapy.
Over the past several years, researchers have developed strategies to eliminate alloreactive T cells from the graft, to expand naturally occurring regulatory T cells, and to select and expand antigen-specific T cells specific for tumor-associated or viral antigens. Incorporation of suicide genes allows the selective destruction of allodepleted or antigen-selected cells after infusion, further increasing the safety and potential applicability of these approaches.
In this review we describe current strategies for adoptive T-cell immunotherapy after hematopoietic stem cell transplantation.
区分移植物抗宿主病与移植物抗白血病反应，并重建针对感染因子的免疫，是异基因造血干细胞移植后T细胞治疗的主要目标。我们描述了对T细胞介导的移植物抗白血病作用及抗病毒反应的深入理解如何为T细胞免疫治疗提供有效方法。
在过去几年中，研究人员已开发出多种策略，包括从移植物中清除同种异体反应性T细胞、扩增天然存在的调节性T细胞，以及选择和扩增针对肿瘤相关或病毒抗原的抗原特异性T细胞。引入自杀基因可在输注后选择性破坏去除同种异体成分的或经抗原选择的细胞，进一步提高这些方法的安全性和潜在适用性。
在本综述中，我们描述了造血干细胞移植后过继性T细胞免疫治疗的当前策略。
